DENVER, May 16, 2011 /PRNewswire/ — VIDA Diagnostics, a
leading developer of quantitative pulmonary imaging software,
announced today the launch of its new Apollo™ Software for
the evaluation of pulmonary disease including chronic obstructive
pulmonary disease (COPD), asthma, and lung cancer, here at the 2011
International Conference of the American Thoracic Society
(ATS).
VIDA also announced that Apollo has been installed at leading
pulmonary centers for validation and clinical use, including
National Jewish Health in Denver, the University of Iowa Hospitals
and Clinics, and Temple University Hospital. National Jewish
Health is the nation’s leading pulmonary hospital and a principal
investigator site for the NIH-sponsored COPDGene study. COPDGene
will evaluate 10,000 patients at various stages of COPD with an
objective to characterize different forms of the disease through
imaging so that effective, personalized treatment strategies can be
developed.
“The groundbreaking work of COPDGene recognizes that COPD may
not be a single disease, and therefore more directed therapies will
be required to effectively treat the disease,” said James D.
Crapo, M.D., Professor of Medicine at National Jewish
Health and a Principal Investigator of COPDGene. “Quantitative
imaging applications, like Apollo, represent an emerging paradigm
shift in evaluating patients with COPD, and have the promise to
effectively classify COPD by disease subtype, enabling
individualized treatment strategies .”
Apollo strengthens VIDA’s groundbreaking solution for lung
airway and parenchymal analysis with algorithmic, workflow and
dataflow improvements for use in a high volume, time constrained
clinical and clinical trial environment. “The increasing
prevalence of COPD, and the growing requirement to objectively
characterize disease and treatment response, increases the
significance of quantitative imaging in evaluating COPD patients,”
said
‘/>”/>
